Nomenclature for alleles of the cytochrome P450 oxidoreductase gene

Pharmacogenetics and Genomics

Volumn 19, Issue 7, 2009, Pages 565-566

  Sim, Sarah C ^a   Miller, Walter L ^b   Zhong, Xiao Bo ^c   Arlt, Wiebke ^d   Ogata, Tsutomu ^e   Ding, Xinxin ^f   Roland Wolf, C ^g   Flück, Christa E ^h   Pandey, Amit V ⁱ   Henderson, Colin J ^g   Porter, Todd D ^j   Daly, Ann K ^k   Nebert, Daniel W ^l   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^f STATE UNIVERSITY OF NEW YORK   (United States)

^g UNIVERSITY OF DUNDEE   (United Kingdom)

^h UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j University of Kentucky   (United States)

^k NEWCASTLE UNIVERSITY   (United Kingdom)

^l UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYTOCHROME P450 REDUCTASE; DRUG METABOLIZING ENZYME; NUCLEOTIDE; SQUALENE MONOOXYGENASE; STEROL 14ALPHA DEMETHYLASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

ALLELE; FRAMESHIFT MUTATION; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; LETTER; MUTATION; NOMENCLATURE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; GENETICS; HUMAN; INTERNET;

ALLELES; GUIDELINES AS TOPIC; HUMANS; INTERNET; NADPH-FERRIHEMOPROTEIN REDUCTASE; POLYMORPHISM, GENETIC; TERMINOLOGY AS TOPIC;

EID: 67651205643     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32832af5b7     Document Type: Letter

References (15)

1. Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004; 36:228-230.
2. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004; 363:2128-2135.
3. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005; 76:729-749.
4. Adachi M, Tachibana K, Asakura Y, Yamamoto T, Hanaki K, Oka A. Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome. Am J Med Genet A 2004; 128A:333-339.
5. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, et al. Cyto-chrome P450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 2005; 90: 414-426.
6. Homma K, Hasegawa T, Nagai T, Adachi M, Horikawa R, Fujiwara I, et al. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab 2006; 91:2643-2649.
7. Antley R, Bixler D. Trapezoidocephaly, midfacial hypoplasia and cartilage abnormalities with multiple synostoses and skeletal fractures. Birth Defects Orig Artic Ser 1975; 11:397-401.
8. Hart SN, Li Y, Nakamoto K, Wesselman C, Zhong XB. Novel SNPs in cytochrome P450 oxidoreductase. Drug Metab Pharmacokinet 2007; 22:322-326.
9. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 2008; 105:1733-1738.
10. Shackleton C, Marcos J, Malunowicz EM, Szarras-Czapnik M, Jira P,Taylor NF, et al. Biochemical diagnosis of Antley-Bixler syndrome by steroid analysis. Am J Med Genet A 2004; 128A:223-231.
11. Kelley RI, Kratz LE, Glaser RL, Netzloff ML, Wolf LM, Jabs EW. Abnormal sterol metabolism in a patient with Antley-Bixler syndrome and ambiguous genitalia. Am J Med Genet 2002; 110:95-102.
12. Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 2008; 18:569-576.
13. Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS, et al. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys 2008; 475:93-99.
14. Hart SN, Wang S, Nakamoto K, Wesselman C, Li Y, Zhong XB. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 2008; 18:11-24.
15. Adachi M, Asakura Y, Matsuo M, Yamamoto T, Hanaki K, Arlt W. POR R457H is a global founder mutation causing Antley-Bixler syndrome with autosomal recessive trait. Am J Med Genet A 2006; 140:633-635.